Coulter Partners announces top hires for VC & PE portfolio companies Q3-2022
Search Highlights
Recent top global hires for Venture Capital and Private Equity backed companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech.
This quarter’s successful placements include:
• Chief Commercial Officer, Rapid molecular diagnostics (Belgium)
• Chief Medical Officer, Radiopharmaceuticals (China)
• Chief Medical Officer, Oncology biotech (US)
• Country Chief Financial Officer, In/outpatient services (Austria)
• Chief R&D Officer, Small molecule therapeutics (UK)
• Chief Communications Officer, Medical research charity (UK)
• SVP Head of Global Clinical Operations, Immuno-oncology biotech (US)
• VP Intellectual Property, Protein degradation technology (UK)
• VP Marketing, Big data discovery (Belgium)
• Head of Clinical Operations, Anticoagulant development (Netherlands)
• Head of Biology, Radiotherapeutics (Germany)
• VP Telehealth, Ophthalmic technologies (France)
• Director Central & Eastern Europe, Drug delivery devices (Ireland)
• Innovation Project Lead, Biomarker, AI / cloud-enabled devices (France)
Newly opened projects include:
• CEO, Cell therapies (Switzerland)
• CEO, Stem cell technologies (UK)
• Chief Business Officer (US), Regenerative medicine (France)
• Chief Medical Officer, Genomic medicine (US)
• Chief Scientific Officer, Oncology biotech (Switzerland)
• Chief Development Officer, Cancer immunotherapies (Singapore)
• Chief Financial Officer, Infectious diseases (US)
• Head of Business Development, Small molecule therapeutics (UK)
• VP CMC, Gene therapy (US)
• Country Manager x2, Digital patient services (Nordics)
• Partner, Digital Health Investments, Life sciences investor (Italy)
• Board Director x2, Not-for-profit (UK)
• Board Director, Oncology immunotherapies (France)
• Board Director, Medical devices (UK)
